Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this prospective, single-centre randomized controlled trial is to
assess the efficacy of three different drugs in treatment of ureteral stents related symptoms
(Beta 3 adrenergic receptor agonist; Mirabegron 50mg) vs. (Alpha 1 adrenergic receptor
antagonist; Tamsulosin 0.4mg) vs. (Anticholinergic; Solifenacin 10 mg) using validated
symptoms questionnaires.
In addition, adverse events of the utilized medications will be monitored during study period
as a secondary objective.